亚太药业 (002370.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	318.2M	323.1M	405.2M	420.6M	373.4M
Cost of Revenue	210.2M	216.1M	278.9M	285.6M	239.8M
Gross Profit	107.9M	107.0M	126.3M	135.0M	133.6M
Operating Expenses
R&D Expense	16.6M	15.5M	14.6M	21.8M	26.1M
SG&A Expense	—	—	—	—	—
General & Admin Expense	48.3M	52.6M	53.4M	60.8M	55.8M
Selling & Marketing Expense	53.9M	52.5M	57.1M	76.6M	72.4M
Other Expenses	—	—	—	—	—
Total Operating Expenses	149.1M	152.2M	151.2M	198.8M	201.0M
Cost and Expenses	359.3M	368.3M	430.1M	484.5M	440.8M
Operating Income (EBIT)	95.7M	90.5M	28.2M	(63.5M)	(116.6M)
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	101.6M	96.4M	34.5M	(11.6M)	(135.3M)
Income Tax Expense	80.2K	124.5K	245.7K	313.3K	(2.6M)
Bottom Line
Net Income	101.5M	96.3M	34.2M	(11.9M)	(132.7M)
Earnings from Cont. Ops	101.5M	96.3M	34.2M	(11.9M)	(132.7M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	101.5M	96.3M	34.2M	(11.9M)	(132.7M)
Per Share
Basic EPS	CN¥0.13	CN¥0.13	CN¥0.05	(CN¥0.02)	(CN¥0.25)
Diluted EPS	CN¥0.13	CN¥0.13	CN¥0.05	(CN¥0.02)	(CN¥0.25)
Revenue Per Share	CN¥0.43	CN¥0.44	CN¥0.59	CN¥0.71	CN¥0.70
Shares
Basic Shares Outstanding	739.3M	740.8M	684.8M	593.8M	530.8M
Diluted Shares Outstanding	739.3M	740.8M	684.8M	593.8M	530.8M
Profitability Metrics
EBITDA	—	122.3M	65.3M	(22.7M)	(74.0M)
D&A	—	31.8M	37.1M	40.8M	42.6M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026